In 1969, a Vietnam War–driven medical challenge led Dr. Larry Hench to develop 45S5 bioactive glass — the first synthetic material to bond directly with living bone. This breakthrough shifted biomaterials from inert implants to regenerative medicine. Acquired by KIC Ventures in 2018, NanoFUSE Biologics is advancing next-generation synthetic biologics to support bone regeneration in modern spine and orthopedic care.

I n 2008, the global financial system did not merely experience a downturn. It suffered a meltdown . Highly leveraged financial products collapsed. Liquidity disappeared. Major financial institutions required emergency intervention to survive. Retirement accounts lost decades of gains in months, not because businesses stopped producing value, but because confidence in financial abstractions evaporated. That moment permanently altered how many investors think about risk. What Actually Broke...

Listening Before You Have Answers Just before I started SpineFrontier, I did what many founders do. I asked people I respected, surgeons and distributors, what they thought. One distributor looked at me and said, “Why would you do that? There are already so many spine companies. How will you compete?” Another question came up repeatedly. “How will you raise venture capital money as a surgeon?” I listened carefully. I took notes. And the truth is, I did not have good answers. What I did have...